Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- 1 December 2015
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 10 (12), 1726-1735
- https://doi.org/10.1097/jto.0000000000000687
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS MutationsJournal of Thoracic Oncology, 2011
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor ProgressionCancer Cell, 2011
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung AdenocarcinomaClinical Cancer Research, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjectsClinical and Experimental Immunology, 2007
- Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Relationship Between K-ras Oncogene Activation and Smoking in Adenocarcinoma of the Human LungJNCI Journal of the National Cancer Institute, 1991